← Back to Screener
Invivyd, Inc. Common Stock (IVVD)
Price$1.03
Value ScoreB
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-65.54%
Price vs S&P 500 (4W)-31.32%
VGM Score56.60
Market Capitalization$303.45M
All Metrics
Book Value / Share (Quarterly)$0.72
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.28
Price vs S&P 500 (YTD)-66.46%
Gross Margin (TTM)92.94%
Net Profit Margin (TTM)-138.90%
EPS (TTM)$-0.36
10-Day Avg Trading Volume2.85M
EPS Excl Extra (TTM)$-0.36
EPS (Annual)$-0.30
ROI (Annual)-21.73%
Gross Margin (Annual)92.99%
Cash / Share (Quarterly)$0.65
Revenue Growth QoQ (YoY)21.59%
ROA (Last FY)-18.96%
Revenue Growth TTM (YoY)52.27%
EBITD / Share (TTM)$-0.37
ROE (5Y Avg)-98.74%
Operating Margin (TTM)-146.38%
Cash Flow / Share (Annual)$-0.21
P/B Ratio1.49x
P/B Ratio (Quarterly)1.81x
Net Income / Employee (Annual)$-430,200
EV / Revenue (TTM)2.14x
ROA (TTM)-41.56%
EPS Incl Extra (Annual)$-0.30
Current Ratio (Annual)7.24x
Quick Ratio (Quarterly)6.21x
3-Month Avg Trading Volume2.92M
52-Week Price Return11.34%
Revenue / Employee (TTM)$457,900
P/S Ratio (Annual)5.68x
Asset Turnover (Annual)0.19x
52-Week High$3.07
EPS Excl Extra (Annual)$-0.30
26-Week Price Return-57.61%
Quick Ratio (Annual)7.07x
13-Week Price Return-40.80%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.47x
Enterprise Value$119.29M
Asset Turnover (TTM)0.30x
Revenue / Employee (Annual)$437,900
Pretax Margin (Annual)-98.25%
Cash / Share (Annual)$0.80
3-Month Return Std Dev107.04%
Net Income / Employee (TTM)$-636,100
ROE (Last FY)-21.73%
EPS Basic Excl Extra (Annual)$-0.30
Receivables Turnover (TTM)5.53x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.36
ROI (TTM)-53.48%
P/S Ratio (TTM)5.43x
Revenue / Share (Annual)$0.31
Price vs S&P 500 (52W)-13.03%
Year-to-Date Return-58.30%
5-Day Price Return-15.57%
EPS Normalized (Annual)$-0.30
ROA (5Y Avg)-67.28%
Net Profit Margin (Annual)-98.25%
Month-to-Date Return-9.65%
EBITD / Share (Annual)$-0.32
Operating Margin (Annual)-103.99%
ROI (5Y Avg)-98.74%
EPS Basic Excl Extra (TTM)$-0.36
P/B Ratio (Annual)2.83x
Pretax Margin (TTM)-138.90%
Book Value / Share (Annual)$0.86
Price vs S&P 500 (13W)-49.06%
Beta0.72x
Revenue / Share (TTM)$0.18
ROE (TTM)-53.48%
52-Week Low$0.48
vGradeB
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.13est. -0.07
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.10
4.10
4.22
4.22
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IVVDInvivyd, Inc. Common Stock | B | B | D | $1.03 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Invivyd Inc is a biopharmaceutical company developing monoclonal antibody therapies for serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), holds FDA emergency use authorization for COVID-19 prevention in immunocompromised patients. The company is advancing pipeline candidates including VYD2311 for COVID-19 and VBY329 for RSV.